LOGIN  |  REGISTER
Assertio

Illumina to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023

January 10, 2023 | Last Trade: US$99.96 0.79 0.80

SAN DIEGO, Jan. 10, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2022 following the close of market on Tuesday, February 7, 2023. 

On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, Chief Executive Officer, and Joydeep Goswami, Chief Strategy and Corporate Development Officer and Interim Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. 

Conference Call Details

The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Tuesday, February 7, 2023. Interested parties may access the live teleconference through the Investor Info section of Illumina's website at investor.illumina.com. Alternatively, individuals can access the call by dialing 844.394.5144 or +1.773.305.6867 outside North America, both with Conference ID 5339523.  To ensure timely connection, please dial in at least ten minutes before the scheduled start of the call.

A replay of the conference call will be posted on Illumina's website after the event and will be available for at least 30 days following.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, and YouTube.

Investors:
Salli Schwartz
+1.858.291.6421
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Media:
David McAlpine
+1.347.327.1336
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page